US2010330037A1PendingUtilityA1

Adenoviral systems and the uses thereof

59
Assignee: HOLM PER SONNEPriority: Dec 28, 2000Filed: Feb 9, 2009Published: Dec 30, 2010
Est. expiryDec 28, 2020(expired)· nominal 20-yr term from priority
Inventors:Per Holm
A61P 35/00A61P 43/00A61K 38/00A61K 48/00C07K 14/4702C12N 2830/008C12N 15/86C12N 2710/10343
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is related to a nucleic acid comprising an adenoviral nucleic acid, which also comprises a nucleic acid sequence coding for YB-1.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
     
     
         47 . A nucleic acid comprising an adenoviral nucleic acid, characterized in that the nucleic acid comprises a nucleic acid sequence coding for YB-1. 
     
     
         48 . The nucleic acid of  claim 47 , characterized in that the adenoviral nucleic acid comprises a nucleic acid coding for E1-B. 
     
     
         49 . The nucleic acid of  claim 48 , characterized in that the adenoviral nucleic acid comprises a nucleic acid coding for E4orf6. 
     
     
         50 . The nucleic acid of  claim 48 , characterized in that a promoter is provided which controls the expression of E1-B. 
     
     
         51 . The nucleic acid of  claim 49 , characterized in that a promoter is provided which controls the expression of E4orf6. 
     
     
         52 . The nucleic acid of  claim 48 , characterized in that E1B is the E1-B 55 kDa protein. 
     
     
         53 . The nucleic acid of the  claim 48 , characterized in that the nucleic acid codes for functionally inactive gene products E1 B and/or E1 and/or E3 and/or E4. 
     
     
         54 . A nucleic acid comprising a nucleic acid coding for YB-1 and a nucleic acid sequence mediating a nuclear transport of YB-1. 
     
     
         55 . The nucleic acid of  claim 54 , characterized in that the nucleic acid sequence mediating the nuclear transport of YB-1 is selected from the group comprising signal sequences and transport sequences. 
     
     
         56 . A nucleic acid comprising an adenoviral nucleic acid, characterized in that the adenoviral nucleic acid comprises a tumour-specific promoter instead of a functional E2 late promoter. 
     
     
         57 . A nucleic acid comprising an adenoviral nucleic acid, characterized in that the adenoviral nucleic acid comprises a tissue-specific promoter instead of a functional E2 late promoter. 
     
     
         58 . The nucleic acid of  claim 57 , characterized in that the adenoviral nucleic acid contains a non-functional E2 early promoter. 
     
     
         59 . An adenoviral replication system comprising an adenoviral nucleic acid, whereby the adenoviral nucleic acid is deficient for the expression of the E1A protein, and comprising a nucleic acid of a helper virus, whereby the nucleic acid of the helper virus comprises a nucleic acid sequence which codes for YB-1. 
     
     
         60 . The adenoviral replication system of  claim 59 , characterized in that the adenoviral nucleic acid and/or the nucleic acid of the helper virus is present as a replicable vector. 
     
     
         61 . A vector, preferably an expression vector, comprising a nucleic acid of  claim 47 ,  54 ,  56  or  57 . 
     
     
         62 . A group of vectors comprising of at least two vectors, whereby the overall group of vectors contains an adenoviral replication system of  claim 60 . 
     
     
         63 . The group of vectors of  claim 62 , characterized in that each component of the adenoviral replication system is located on a suitable vector, preferably an expression vector. 
     
     
         64 . The group of vectors of  claim 62 , characterized in that at least two components of the adenoviral replication system are located on a vector of the group of vectors. 
     
     
         65 . An adenovirus comprising a nucleic acid of  claim 47 ,  54 ,  56  or  57 . 
     
     
         66 . The adenovirus of  claim 65  comprising a capsid. 
     
     
         67 . A cell comprising a nucleic acid of  claim 47 ,  54 ,  56  or  57  and/or an adenoviral replication system of  claim 60  and/or a vector of  claim 61  and/or a group of vectors of  claim 62  and/or an adenovirus of  claim 65 . 
     
     
         68 . Use of a nucleic acid of  claim 47 ,  54 ,  56  or  57  and/or an adenoviral replication system of  claim 60  and/or a vector of  claim 61  and/or a group of vectors of  claim 62  and/or an adenovirus of  claim 65  and/or a cell  claim 67  for the manufacture of a medicament. 
     
     
         69 . The use of  claim 68 , characterized in that the medicament is used for the treatment and/or prophylaxis of tumour diseases. 
     
     
         70 . The use of  claim 68 , characterized in that the medicament additionally contains a pharmaceutically effective compound. 
     
     
         71 . The use of  claim 70 , characterized in that the pharmaceutically effective compound is selected from the group comprising cytostatic agents, whereby the cytostatic agents are preferably selected from the group comprising cis-platinum, Taxol, Daunoblastin, Adriamycin and Mitoxantron. 
     
     
         72 . Use of a nucleic acid of  claim 47 ,  54 ,  56  or  57  and/or an adenoviral replication system of  claim 60  and/or a vector of  claim 58  and/or a group of vectors of  claim 62  and/or an adenovirus of  claim 65  and/or a cell of  claim 67  for the manufacture of a medicament for the treatment and/or prophylaxis of tumour diseases, whereby YB-1 is located in the nucleus of the tumour cells independent of the cell cycle. 
     
     
         73 . The use of  claim 72 , characterized in that the nucleic acid codes for an adenoviral nucleic acid and that the adenoviral nucleic acid is E1B-deficient, and in particular E1B 55 kDa-deficient. 
     
     
         74 . The use of  claim 72 , characterized in that the adenovirus is E1B-deficient, and in particular E1B 55 kDa-deficient. 
     
     
         75 . The use of  claim 72 , characterized in that the nucleic acid codes for an adenoviral nucleic acid and that the adenoviral nucleic acid codes for E1B, and codes in particular for E1B 55 kDa. 
     
     
         76 . The use of  claim 72 , characterized in that the adenovirus expresses E1B, and expresses in particular E1B 55 kDa. 
     
     
         77 . The use of  claims 72 , characterized in that the adenoviral nucleic acid codes for E1 A. 
     
     
         78 . The use of  claims 72 , characterized in that the adenovirus expresses E1A. 
     
     
         79 . The use of  claim 76 , characterized in that the tumour and/or the tumour disease is selected from the group comprising p53-positive tumours, p53-negative tumours, malignant tumours, benign tumours and combinations thereof. 
     
     
         80 . A method for the screening of patients who can be treated with an E1B-deficient, preferably E1B 55 kDa-deficient adenovirus characterized by the following steps:
 examining a sample of the tumour tissue and   determining whether YB-1 is located in the nucleus independently of the cell cycle.   
     
     
         81 . The method of  claim 80 , characterized in that the tumour tissue is examined using antibodies against YB-1.

Join the waitlist — get patent alerts

Track US2010330037A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.